322 related articles for article (PubMed ID: 9013963)
1. Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice.
Epstein SL; Lo CY; Misplon JA; Lawson CM; Hendrickson BA; Max EE; Subbarao K
J Immunol; 1997 Feb; 158(3):1222-30. PubMed ID: 9013963
[TBL] [Abstract][Full Text] [Related]
2. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.
Sambhara S; Kurichh A; Miranda R; Tumpey T; Rowe T; Renshaw M; Arpino R; Tamane A; Kandil A; James O; Underdown B; Klein M; Katz J; Burt D
Cell Immunol; 2001 Aug; 211(2):143-53. PubMed ID: 11591118
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of protective immunity against influenza virus infection in mice without antibodies.
Epstein SL; Lo CY; Misplon JA; Bennink JR
J Immunol; 1998 Jan; 160(1):322-7. PubMed ID: 9551987
[TBL] [Abstract][Full Text] [Related]
4. Beta 2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase.
Epstein SL; Misplon JA; Lawson CM; Subbarao EK; Connors M; Murphy BR
J Immunol; 1993 Jun; 150(12):5484-93. PubMed ID: 8390536
[TBL] [Abstract][Full Text] [Related]
5. Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes.
Nguyen HH; van Ginkel FW ; Vu HL; McGhee JR; Mestecky J
J Infect Dis; 2001 Feb; 183(3):368-76. PubMed ID: 11133367
[TBL] [Abstract][Full Text] [Related]
6. Protection against lethal influenza virus encephalitis by intranasally primed CD8+ memory T cells.
Stevenson PG; Hawke S; Bangham CR
J Immunol; 1996 Oct; 157(7):3065-73. PubMed ID: 8816416
[TBL] [Abstract][Full Text] [Related]
7. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity.
Liew FY; Russell SM; Appleyard G; Brand CM; Beale J
Eur J Immunol; 1984 Apr; 14(4):350-6. PubMed ID: 6609824
[TBL] [Abstract][Full Text] [Related]
8. Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues.
Nguyen HH; Moldoveanu Z; Novak MJ; van Ginkel FW; Ban E; Kiyono H; McGhee JR; Mestecky J
Virology; 1999 Feb; 254(1):50-60. PubMed ID: 9927573
[TBL] [Abstract][Full Text] [Related]
9. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1.
Morrison LA; Knipe DM
Virology; 1997 Dec; 239(2):315-26. PubMed ID: 9434723
[TBL] [Abstract][Full Text] [Related]
10. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity.
Liang S; Mozdzanowska K; Palladino G; Gerhard W
J Immunol; 1994 Feb; 152(4):1653-61. PubMed ID: 8120375
[TBL] [Abstract][Full Text] [Related]
11. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge.
Fu TM; Guan L; Friedman A; Schofield TL; Ulmer JB; Liu MA; Donnelly JJ
J Immunol; 1999 Apr; 162(7):4163-70. PubMed ID: 10201942
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice.
Bodewes R; Kreijtz JH; Hillaire ML; Geelhoed-Mieras MM; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
J Gen Virol; 2010 Jul; 91(Pt 7):1743-53. PubMed ID: 20335492
[TBL] [Abstract][Full Text] [Related]
13. Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections.
Sun K; Ye J; Perez DR; Metzger DW
J Immunol; 2011 Jan; 186(2):987-93. PubMed ID: 21160043
[TBL] [Abstract][Full Text] [Related]
14. Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells.
Benton KA; Misplon JA; Lo CY; Brutkiewicz RR; Prasad SA; Epstein SL
J Immunol; 2001 Jun; 166(12):7437-45. PubMed ID: 11390496
[TBL] [Abstract][Full Text] [Related]
15. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus.
Asahi-Ozaki Y; Yoshikawa T; Iwakura Y; Suzuki Y; Tamura S; Kurata T; Sata T
J Med Virol; 2004 Oct; 74(2):328-35. PubMed ID: 15332283
[TBL] [Abstract][Full Text] [Related]
16. Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules.
Tamura S; Funato H; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T
Eur J Immunol; 1991 Jun; 21(6):1337-44. PubMed ID: 1646112
[TBL] [Abstract][Full Text] [Related]
17. Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus.
Kreijtz JH; Bodewes R; van den Brand JM; de Mutsert G; Baas C; van Amerongen G; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
Vaccine; 2009 Aug; 27(36):4983-9. PubMed ID: 19538996
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.
Tamura S; Tanimoto T; Kurata T
Jpn J Infect Dis; 2005 Aug; 58(4):195-207. PubMed ID: 16116250
[TBL] [Abstract][Full Text] [Related]
19. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice.
Kreijtz JH; Bodewes R; van Amerongen G; Kuiken T; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
Vaccine; 2007 Jan; 25(4):612-20. PubMed ID: 17005299
[TBL] [Abstract][Full Text] [Related]
20. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies.
Lo CY; Wu Z; Misplon JA; Price GE; Pappas C; Kong WP; Tumpey TM; Epstein SL
Vaccine; 2008 Apr; 26(17):2062-72. PubMed ID: 18378366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
